Protalix BioTherapeutics, Inc. (PLX) P/E Ratio History
Historical price-to-earnings valuation from 2015 to 2025
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of February 28, 2026, Protalix BioTherapeutics, Inc. (PLX) trades at a price-to-earnings ratio of 78.7x, with a stock price of $2.88 and trailing twelve-month earnings per share of $0.07.
The current P/E is 146% above its 5-year average of 32.0x. Over the past five years, PLX's P/E has ranged from a low of 1.2x to a high of 116.3x, placing the current valuation at the 92th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, PLX trades at a 232% premium to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, PLX commands a significant premium over the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our PLX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Commercial Rare Disease Biopharma peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
VRTXVertex Pharmaceuticals Incorporated | $126B | 32.4 | 3.91 | +837% |
BMRNBioMarin Pharmaceutical Inc. | $12B | 34.3 | - | +1186%Best |
PTCTPTC Therapeutics, Inc. | $5B | 8.8 | - | +264% |
CORTCorcept Therapeutics Incorporated | $4B | 43.5 | - | -33% |
CPRXCatalyst Pharmaceuticals, Inc. | $3B | 13.7 | 0.73Best | +28% |
BCRXBioCryst Pharmaceuticals, Inc. | $2B | 7.2Lowest | - | +381% |
HRMYHarmony Biosciences Holdings, Inc. | $2B | 10.5 | - | +8% |
PLXProtalix BioTherapeutics, Inc. | $218M | 78.7 | - | -63% |
SLNOSoleno Therapeutics, Inc. | $145,692 | 100.2 | - | +109% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | $2.22 | $0.07 | 31.5x | -2% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $1.48 | $0.07 | 20.0x | -38% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $2.56 | $0.04 | 60.8x | +90% |
| FY2024 Q4 | $1.88 | $0.03 | 64.2x | +100% | |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $1.26 | $0.05 | 27.9x | -13% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $1.78 | $0.06 | 32.3x | +1% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $1.66 | $0.07 | 25.5x | -20% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $2.00 | $0.02 | 116.3x | +263% |
| FY2016 Q3 | Fri Sep 30 2016 00:00:00 GM | $5.70 | $4.61 | 1.2x | -96% |
| FY2016 Q2 | $6.40 | $4.91 | 1.3x | -96% | |
| FY2016 Q1 | $8.40 | $5.51 | 1.5x | -95% | |
| FY2015 Q4 | $10.20 | $5.81 | 1.8x | -95% |
Average P/E for displayed period: 32.0x
See PLX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PLX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare PLX vs AGIO
See how PLX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is PLX stock overvalued or undervalued?
PLX trades at 78.7x P/E, above its 5-year average of 32.0x. The 92th percentile ranking indicates a premium to historical valuation.
How does PLX's valuation compare to peers?
Protalix BioTherapeutics, Inc. P/E of 78.7x compares to sector median of 23.7x. The premium reflects expected growth above peers.
What is PLX's PEG ratio?
PLX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2015-2025.